Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea

PURPOSE: The purpose of this study was to investigate the feasibility and survival benefits of combined treatment with radiotherapy and adjuvant temozolomide (TMZ) in a Korean sample. MATERIALS AND METHODS: A total of 750 Korean patients with histologically confirmed glioblastoma multiforme, who rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Byung Sup, Seol, Ho Jun, Nam, Do-Hyun, Park, Chul-Kee, Kim, Il Han, Kim, Tae Min, Kim, Jeong Hoon, Cho, Young Hyun, Yoon, Sang Min, Chang, Jong Hee, Kang, Seok-Gu, Kim, Eui Hyun, Suh, Chang-Ok, Jung, Tae-Young, Lee, Kyung-Hwa, Kim, Chae-Yong, Kim, In Ah, Hong, Chang-Ki, Yoo, Heon, Kim, Jin Hee, Kang, Shin-Hyuk, Kang, Min Kyu, Kim, Eun-Young, Kim, Sun-Hwan, Chung, Dong-Sup, Hwang, Sun-Chul, Song, Joon-Ho, Cho, Sung Jin, Lee, Sun-Il, Lee, Youn-Soo, Ahn, Kook-Jin, Kim, Se Hoon, Lim, Do Hun, Gwak, Ho-Shin, Lee, Se-Hoon, Hong, Yong-Kil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266397/
https://www.ncbi.nlm.nih.gov/pubmed/27384161
http://dx.doi.org/10.4143/crt.2015.473
Descripción
Sumario:PURPOSE: The purpose of this study was to investigate the feasibility and survival benefits of combined treatment with radiotherapy and adjuvant temozolomide (TMZ) in a Korean sample. MATERIALS AND METHODS: A total of 750 Korean patients with histologically confirmed glioblastoma multiforme, who received concurrent chemoradiotherapy with TMZ (CCRT) and adjuvant TMZ from January 2006 until June 2011, were analyzed retrospectively. RESULTS: After the first operation, a gross total resection (GTR), subtotal resection (STR), partial resection (PR), biopsy alone were achieved in 388 (51.7%), 159 (21.2%), 96 (12.8%), and 107 (14.3%) patients, respectively. The methylation status of O(6)-methylguanine-DNA methyltransferase (MGMT) was reviewed retrospectively in 217 patients. The median follow-up period was 16.3 months and the median overall survival (OS) was 17.5 months. The actuarial survival rates at the 1-, 3-, and 5-year OS were 72.1%, 21.0%, and 9.0%, respectively. The median progression-free survival (PFS) was 10.1 months, and the actuarial PFS at 1-, 3-, and 5-year PFS were 42.2%, 13.0%, and 7.8%, respectively. The patients who received GTR showed a significantly longer OS and PFS than those who received STR, PR, or biopsy alone, regardless of the methylation status of the MGMT promoter. Patients with a methylated MGMT promoter also showed a significantly longer OS and PFS than those with an unmethylated MGMT promoter. Patients who received more than six cycles of adjuvant TMZ had a longer OS and PFS than those who received six or fewer cycles. Hematologic toxicity of grade 3 or 4 was observed in 8.4% of patients during the CCRT period and in 10.2% during the adjuvant TMZ period. CONCLUSION: Patients treated with CCRT followed by adjuvant TMZ had more favorable survival rates and tolerable toxicity than those who did not undergo this treatment.

Ejemplares similares